Christophe L. T.
- Country
- France
- Department
- Department of Drug Development and Innovation
Research Overview
- Safety and Efficacy Evaluation of RO7759065 with Atezolizumab in Patients with Locally Advanced or Metastatic Solid Tumors
- Phase 1-2 Study Investigating Safety, Tolerability, Pharmacokinetics and Preliminary Antitumor Activity of Various Combinations of BGB-A425 and LBL-007 with Tislelizumab in Patients with Advanced Solid Tumors
- Phase 2 Study of MK-7684A (Pembrolizumab, Vibostolimab) With or Without Additional Anticancer Agents in Advanced Solid Tumors Expressing PD-L1
Data & Insights
Has run more than one trial at 15 of 41 partner sites.
Specializations
Head and Neck Cancer Focus
The investigator specializes in treating head and neck squamous cell carcinoma (HNSCC), with particular emphasis on both localized and metastatic disease states. Their expertise extends to recurrent and metastatic cases as well as HPV-related oropharyngeal cancers.
- Locoregionally Advanced HNSCC
- Recurrent/Metastatic Disease Management
- HPV-Associated Malignancies
Advanced Solid Tumors
The investigator has extensive experience in treating various advanced solid malignancies, including esophageal squamous cell carcinoma, ovarian cancer, and gastric cancer. Their work encompasses both locally advanced and metastatic presentations.
- Melanoma Treatment
- Triple Negative Breast Cancer
- Non-small Cell Lung Cancer
Immunotherapy Applications
The investigator focuses on novel immunotherapy approaches and combination treatments, particularly in the context of PD-L1 positive cancers. Their work includes evaluation of various immunotherapy combinations for treatment-naive and previously treated patients.
- First-line Immunotherapy
- Combination Therapy Strategies
- Novel Therapeutic Approaches
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.